Welcome to our dedicated page for Paragon 28 news (Ticker: FNA), a resource for investors and traders seeking the latest updates and insights on Paragon 28 stock.
Paragon 28 Inc (FNA) is a leading innovator in foot and ankle orthopedic devices, specializing in surgical solutions that enhance patient outcomes. This news hub provides investors and healthcare professionals with essential updates on the company’s financial performance, product developments, and industry leadership.
Access real-time announcements including quarterly earnings reports, FDA-cleared device launches, and strategic partnerships with surgical institutions. Our curated collection features regulatory milestones, clinical trial results, and executive commentary – all critical for understanding FNA’s position in the $5B+ global foot and ankle device market.
Key updates cover innovative implant systems, surgeon training initiatives, and manufacturing expansions that demonstrate Paragon 28’s commitment to advancing orthopedic care. Bookmark this page for verified updates on procedural innovations like fracture fixation solutions and deformity correction technologies.
Paragon 28, a leading medical device company, reported a record net revenue of $61.1 million for the first quarter of 2024, up 17.4% from the same period in 2023. The company also reaffirmed its 2024 net revenue guidance of $249 million to $259 million, expecting 15.1% to 19.7% growth compared to 2023. Despite a decrease in gross profit margin and an increase in operating expenses, the company remains optimistic about sustainable growth driven by new product launches and expanded commercial channels.
Paragon 28, Inc. (NYSE: FNA) will be presenting at the Bank of America Securities 2024 Healthcare Conference. The Chairman and CEO, Albert DaCosta, and Interim CFO, Krissy Wright, will participate in a fireside chat on May 14, 2024. The event will be live webcasted and archived on the investor relations section of the Company's website.